Regarding renal cell carcinoma from a US perspective, nivolumab was cost-effective compared to everolimus [50], and nivolumab with ipilimumab was cost-effective compared to sunitinib in both cases with a PD-L1 test, and a $150,000/QALY threshold [48] generated a gain of 0.34 QALYs and 0.98 QALYs, respectively. The gene discussed is CD274; the disease is hereditary clear cell renal cell carcinoma.